Compare Nucor Corporation (NUE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs TransMedics Group Inc — how do they compare? Nucor Corporation trades at $257.93 (market cap $58.51B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Nucor Corporation is far larger — about 19.5× TransMedics Group Inc's market cap, and Nucor Corporation pays a 0.87% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NUE | TMDX | |
|---|---|---|
Market Cap | $58.51B | $3.00B |
Sector | Basic Materials | Technology |
52-Week High | $274.74 | $150.42 |
52-Week Low | $131.78 | $61.99 |
Enterprise Value | $62.92B | $3.39B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $256.4, down 1.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the stock benefits from positive sentiment around U.S. steel demand and tariff protections. The company maintains solid profitability with a net margin of 7.99% and ROE of 13.52%, though revenue has moderated from 2022 peaks.
Outlook is positive with a consensus price target of $281.38, implying ~10% upside. Key opportunities include infrastructure demand and new capacity, while risks involve cyclical steel industry pressures and volatile cash flows. Institutional buying, like CalSTRS' increased stake, supports confidence.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
